American Cancer Society

With Colorectal Cancer Rates Rising, the American Cancer Society and Colorectal Cancer Alliance Join Forces to Increase Screening

Retrieved on: 
Thursday, February 29, 2024
Large intestine, Ulcerative colitis, Incidence, American Cancer Society, Woman, Crohn's disease, Diet, Colorectal cancer, Smoking, Cancer, ACS, Hereditary nonpolyposis colorectal cancer, Weight loss, Polyp, Colorectal Cancer Alliance, Exercise, Calcium, Meat, Risk, Weakness, Survival rate, Alaska Natives, Vegetable, Rectum, USPSTF, Fatigue, Chronic pain, Death, Black, Locator, Ageing, Dairy

ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.

Key Points: 
  • ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.
  • According to the American Cancer Society's Cancer Fact & Figures, 2024 report , colorectal cancer is now the leading cause of cancer death in men and the second in women under 50 years old.
  • "By joining forces with the Colorectal Cancer Alliance, we can reach more individuals and empower them with vital information that can save lives."
  • Matching an American Cancer Society 2018 update to colorectal cancer screening guidelines , and the Alliance's call for earlier screening, the United States Preventive Services Task Force (USPSTF) released a recommendation statement lowering the age to begin colorectal cancer screening from age 50 to age 45 in 2021.

Reese Pharmaceutical Launches New At-Home Colon Cancer Screening Test

Retrieved on: 
Tuesday, February 27, 2024
American Cancer Society, Woman, Colorectal cancer, Colonoscopy, Blood, FDA, OTC, Cough, Food, Pharmacy, Polyp, Sale, FIT, Diverticulitis, Fecal immunochemical test, Cancer, Food and Drug Administration, Colitis, Insurance, Pharmaceutical industry

CLEVELAND, Feb. 27, 2024 /PRNewswire/ -- Reese Pharmaceutical is expanding its over-the-counter (OTC) diagnostic portfolio with the launch of ColoTest®, an at-home Fecal Immunochemical Test (FIT) that identifies the presence of hidden blood in the stool in support of the early detection of colon cancer or gastrointestinal disorders such as colitis, diverticulitis, and polyps.

Key Points: 
  • A recent report by the American Cancer Society revealed a troubling spike in new colon and rectal cancer diagnoses across the US.
  • "90% of colon cancer-related deaths are thought to be preventable if caught early, and yet more than 29 million Americans are not screening for it.
  • With colon cancer rates on the rise, it is more important than ever for people to be proactive.
  • This test is performed in the comfort of your own home with results at home as soon as 1 minute," said Jeffrey Reese, President, of Reese Pharmaceutical.

Color Health Named a Strategic Ally of the Blue Cross Blue Shield National Labor Office

Retrieved on: 
Tuesday, February 27, 2024
American Cancer Society, International Brotherhood of Teamsters, Health, ACS, Cancer, Strategic alliance, Survival rate, Death, Family, Diagnosis, NLO, BCBS, Union, Partnership, Nursing

BURLINGAME, Calif., Feb. 27, 2024 /PRNewswire/ -- Color Health has become a Strategic Alliance partner of the Blue Cross Blue Shield (BCBS) National Labor Office (NLO), paving the way for union leaders to address the growing impact of cancer. This collaboration specifically promotes a more comprehensive approach to addressing cancer – beginning with evidence-based guidelines and full clinical care management from prevention through diagnosis. The alliance will address the high costs associated with late-stage cancer treatment and acute care utilization to support better survival rates and reduced healthcare costs for participating union populations.

Key Points: 
  • BURLINGAME, Calif., Feb. 27, 2024 /PRNewswire/ -- Color Health has become a Strategic Alliance partner of the Blue Cross Blue Shield (BCBS) National Labor Office (NLO), paving the way for union leaders to address the growing impact of cancer.
  • This collaboration specifically promotes a more comprehensive approach to addressing cancer – beginning with evidence-based guidelines and full clinical care management from prevention through diagnosis.
  • "Color's approach focuses on delivering care to union members where they are, whether that's at home or on a job site.
  • This strategic alliance will help union leaders and members take powerful steps towards proactive healthcare, ultimately saving lives and reducing costs."

THE PROSTATE CANCER FOUNDATION AND THE AMERICAN CANCER SOCIETY ANNOUNCE FIRST ACS-PCF YOUNG INVESTIGATOR AWARD

Retrieved on: 
Thursday, February 22, 2024
Prostate Cancer Foundation, University College London, American Cancer Society, Doctor of Philosophy, Prostate cancer, PCF, PARP, ACS, Hospital, Geography, Mentorship, Organization, Patient, Health equity, Cone Health Women's Hospital, Research, Cancer, Partnership

LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and the American Cancer Society (ACS) today announced the ACS-PCF Young Investigator Award totaling $225,000 over three years to support a novel health equity research project that aims to reduce disparities in access to modern prostate cancer care in rural settings.

Key Points: 
  • LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and the American Cancer Society (ACS) today announced the ACS-PCF Young Investigator Award totaling $225,000 over three years to support a novel health equity research project that aims to reduce disparities in access to modern prostate cancer care in rural settings.
  • One in eight men in the U.S. will be diagnosed with prostate cancer in his lifetime, and it is the most commonly diagnosed non-skin cancer in men1.
  • "The Prostate Cancer Foundation has been funding research to understand and address prostate cancer disparities for more than 30 years," said Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, PCF.
  • "We are thrilled to have Dr. Cole as our ACS-PCF Young Investigator," said William Dahut, MD, Chief Scientific Officer, American Cancer Society.

HEALTH GROUPS STRANGELY OPPOSE EFFECTIVE AND PROVEN SMOKING CESSATION PRODUCTS

Retrieved on: 
Wednesday, February 21, 2024
Nicotine, Smoking, Herbal cigarette, Smoke, Heart, Federation, Stroke, American Cancer Society, Organization, Canadian Lung Association, Tobacco, History, Smoker

TORONTO, Feb. 21, 2024 /CNW/ - Public health groups across the country have found a new enemy in their war on nicotine: smoking cessation products.

Key Points: 
  • TORONTO, Feb. 21, 2024 /CNW/ - Public health groups across the country have found a new enemy in their war on nicotine: smoking cessation products.
  • These so-called health groups are pushing to make life saving products harder to buy and less appealing than cigarettes.
  • Shouldn't they be making sure that smoking cessation products are available to adults who smoke and easy for them to purchase?"
  • We will fight for all kinds of effective smoking cessation products."

Award Winning Consultancy Announces Formation of Foundation

Retrieved on: 
Tuesday, February 20, 2024
MLT, Partnership, American Scouting overseas, American Cancer Society, Student, DEI, Research

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Acquis Consulting Group (Acquis) recently announced the formation of the Acquis Foundation .

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Acquis Consulting Group (Acquis) recently announced the formation of the Acquis Foundation .
  • Since its inception, the foundation has already pledged $600,000 toward social responsibility programs and initiatives, with plans to continue to seed exceptional and innovative programs, distributing more than $100,000 annually.
  • "Acquis Foundation allows us to leverage our strategic expertise, collaborate with our partners and make a meaningful impact in the community."
  • "Acquis Foundation allows us to leverage our strategic expertise, collaborate with our partners, and develop an even greater and meaningful impact in the community," says Joanna Sears, Acquis Foundation Board Member and Chief Operating Officer of Acquis Consulting Group.

City Furniture Selects Elite Rewards "Sales Vendor of the Year" 2023

Retrieved on: 
Tuesday, February 20, 2024
Merchandising, American Cancer Society, American Heart Association, Organic, Mastercard, National Urban League, COVID, Elite, Humanity, GWP, Partnership

ST. PETERSBURG, Fla., Feb. 20, 2024 /PRNewswire/ -- Elite Rewards, a consumer incentive marketing company based in Tampa, Florida received City Furniture's "Sales Vendor of the Year" Award for 2023 presented by CEO Andrew Koenig for its continued partnership and success growing business through its "Test Rest – Get & Give" and Gift with Purchase (GWP) programs.

Key Points: 
  • "Elite Rewards is always looking to evolve what customers desire as a gift, they're innovative and timely.
  • City Furniture also recognized Elite for its success in increasing conversion of in-store traffic into additional sales utilizing Elite's "Test Rest – Get & Give'' mattress program.
  • City Furniture introduced the concept of "Get $25, Give $25", to customers testing mattresses while visiting the store.
  • Those wishing to learn more about Elite Rewards, please visit www.eliterewards.biz , or contact J.B. Siegel, Press contact at [email protected] , tel: 727-543-8100.

Health groups call on Federal government to deliver on its commitment to protect kids against nicotine addiction

Retrieved on: 
Monday, February 19, 2024
Smoke, NRT, Social media, Television, Minor, Nicotine, Smoking, Imperial Brands, Sale, Heart, Federation, Smoker, Government, Advertising, Health, American Cancer Society, Canadian Cancer Society, Columbia, Spokesperson, Menthol, The Hill Times, Tobacco, Public affairs, Minister

While the government's existing proposal would exempt mint/menthol, health groups have argued that a complete ban on non-tobacco flavours is required to protect young people from nicotine addiction, as mint/menthol is the second-most popular flavour amongst youth and young adults .

Key Points: 
  • While the government's existing proposal would exempt mint/menthol, health groups have argued that a complete ban on non-tobacco flavours is required to protect young people from nicotine addiction, as mint/menthol is the second-most popular flavour amongst youth and young adults .
  • The ad also calls for swift action to protect minors against the sale and promotion of nicotine pouches, namely by making them a prescription-only product.
  • Making nicotine pouches available on a prescription-only basis would give time to both federal and provincial governments to establish a proper regulatory framework.
  • We hope that the government will be consistent in protecting kids from nicotine addiction and will rapidly move to ban all flavours in vaping products.

New Guidance Published in The Lancet Recommends Early Intervention and Use of BIS to Reduce Impact of Arm Lymphedema on Breast Cancer Patients

Retrieved on: 
Thursday, February 15, 2024
Breast cancer, American Cancer Society, Survivor, BIS, Education, MD, FDA, Lymphedema, Quality of life, MBA, Manuscript, Risk, Wastewater treatment, Lancet, Health, Patient, Melanoma

CARLSBAD, Calif., Feb. 15, 2024 /PRNewswire/ -- ImpediMed, a pioneer in the field of medical technology, announced a significant advancement in the fight against breast cancer-related lymphedema, a common but often overlooked condition affecting breast cancer survivors. Leading medical journal eClinicalMedicine, part of The Lancet Discovery Science, recently published new clinical guidance advocating for early detection and prevention strategies, underscoring the validity and efficacy of ImpediMed's innovative approach.

Key Points: 
  • Leading medical journal eClinicalMedicine, part of The Lancet Discovery Science, recently published new clinical guidance advocating for early detection and prevention strategies, underscoring the validity and efficacy of ImpediMed's innovative approach.
  • At the center of these recommendations is bioimpedance spectroscopy (BIS), a cutting-edge technology pioneered by ImpediMed, designed to help detect lymphedema in its early stages before it becomes a significant problem.
  • According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk.
  • The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema.

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors

Retrieved on: 
Thursday, February 15, 2024
Leukemia, Division, American Cancer Society, Doctor of Philosophy, Immunotherapy, UPMC Shadyside, Drug development, UPMC, Leukemia & Lymphoma Society, University, Patient, UPMC Hillman Cancer Center, Explainable artificial intelligence, Research, Cancer, Management

PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.

Key Points: 
  • PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.
  • Dusty Majumdar, PhD, CEO of PredxBio
    "We are thrilled and privileged to announce the appointment of Dr. Marks as the Chairman of PredxBio's Board of Directors," expressed Dusty Majumdar, PhD, CEO of PredxBio.
  • "I am honored to serve as Chairman of the Board of Directors at PredxBio," commented Dr. Marks.
  • Supported by over 20 peer-reviewed publications, 4000+ citations, and numerous patents, PredxBio contributes significantly to improving cancer care.